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and 1 year following initiation of LEN were identified in a US health plan claims
database (7/1/2007-6/30/2011). Persistence was defined as days from the first LEN
treatment to the earlier of either the date of discontinuation or end of the follow-up
period. Adherence was measured by the medication possession ratio. Indicators of
disease control included in this study were inpatient hospitalization(s) and number
of ER visits. Disease-related complications included evidence of skeletal-related
events (SREs) defined as fracture, spinal cord compression, or radiation to the bone;
and sepsis. RESULTS: Among the 605 patients meeting the inclusion criteria, per-
sistency with lenalidomide averaged 6.0 months (median  4.9) with 57.9% of
patients being persistent for the entire year. A one month increase in persistence
was associated with a lower probability of SREs (OR0.96; p0.078), sepsis
(OR0.86; p0.001), and relapse or disease progression (OR0.78; p0.001). The
probability of an inpatient hospitalization (OR0.68; p-value0.001) and additional
ER visits (OR0.83; p0.002) were both lower with better persistence. A higher
medication possession ratio measured in year 1 was associated with increased
overall survival (p0.007).CONCLUSIONS: This analysis demonstrates that contin-
uous treatment with LEN improves disease control in MM patients, as well as
reduces health care utilization and related costs as indicated by the lower risk of
hospitalizations and fewer ER visits.
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OBJECTIVES: Since 2008, teenage girls are being vaccinated against Human Papil-
lomavirus (HPV) in Europe. The vaccine coverage did not reach high uptake. The
aim of this study is to design a dynamic transmission framework to model HPV-
transmission in the population in order to predict epidemiologic and economic
consequences of population-based HPV vaccination programs. METHODS: A dy-
namic transmission model was designed including 7 different HPV-types to predict
the epidemiologic and economic consequences of HPV-vaccination. Dutch age-
specific HPV-prevalence and cervical cancer incidence and mortality data were
used to calibrate the model assuming a steady state. The consequence of HPV-
vaccination was analyzed in different scenarios. In particular, the age of the vac-
cinee, inclusion of boys, and a reduced screening compliance was assessed. In
sensitivity analyses, the vaccination coverage, duration of vaccine-induced protec-
tion, and vaccine choice was varied. RESULTS: Vaccination of 50% of girls against
HPV infection results in a 56% overall reduction in cervical cancer incidence. The
model predicted outcomes are highly sensitive for the duration of vaccine-induced
protection and the vaccination coverage. If vaccination will only provide 20-years
of protection a 32% reduction in cervical cancer incidence was observed. HPV16 and
18 will be eradicated from the general population if vaccine coverage is 90%.
Vaccination at an older age still provides a relevant number of cases averted how-
ever vaccination before sexual debut remains most efficient. Vaccination of boys
was found to be not an effective alternative. CONCLUSIONS: HPV vaccination was
found to be highly effective in reducing the burden of cervical cancer. The model
predicted outcomes are most sensitive for vaccine-induced duration of protection.
Vaccination of girls at an older age can be considered to further reduce the inci-
dence of cervical cancer.
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OBJECTIVES: The worldwide incidence of melanoma is increasing rapidly. Two
chemotherapy regimens are used for treatment of Malignant Melanoma: single
agent intravenous Dacarbazine (DTIC) and oral Temozolomide (TMZ). TMZ has
greater cost in Iran so we aimed to conduct a meta analysis to compare the efficacy
of two drugs. METHODS: To compare the efficacy of these two drugs, a systematic
review and meta-analysis were conducted and published articles, comparing use
of Dacarbazine and Temozolomide in treatment of Malignant Melanoma were re-
viewed. For this purpose, Pubmed, Scopous, Web of Science and Cochrane Central
Register of Controlled Trials were searched and the search terms were: “Dacarba-
zine” and “Temozolomide” and “ Malignant Melanoma”. Data were collected from
inception to 2012. “Response to treatment” includes:” complete response (CR)”,”
partial response (PR)” and “stable disease (SD)” and side effects were the key out-
comes of interest. RESULTS: The meta-analysis included 3 RCTS and involved 1314
patients with malignant melanoma. Approximately half of them were allocated to
the TMZ arm and half to the DTIC arm. Comparison of TMZ with DTIC yielded a
nonsignificant relative risk (RR) of 0.83 (95% confidence interval of 0.26-2.64,
P0.76) for complete response. A nonsignificant RR of 1.35 (95% CI of 0.95-1.91,
P0.1) for partial response. A nonsignificant RR of 1.05 (95% CI of 0.85-1.3, P0.65)
for stable disease and a nonsignificant RR of 1.15 (95% CI of 0.74-1.79, P0.55) for
fatigue ( a side effect). CONCLUSIONS: The potential value of oral versus intrave-
nous chemotherapy is obvious but considering health outcome and not significant
difference in efficacy between these two drugs and that TMZ even does not have
less side effects and has higher cost of treatment in Iran, we suggest DTIC as a
first-choice treatment for Malignant Melanoma.
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OBJECTIVES: To systematically review the currently available clinical and cost-
effectiveness evidence on proton beam radiotherapy (PBRT) for cancers mostly
affecting the eye: uveal melanoma, retinoblastoma and metastatic tumors.
METHODS: A systematic literature search was conducted for published and un-
published cost-effectiveness and clinical data (comparative studies) on the eye
cancer population, treated with proton radiation, using a number of medical data-
bases (PubMed, EMBASE, Cochrane Library). In addition, clinical trial registries
were searched, reference lists of included studies and of reviews were screened for
missed studies. Searches took place in January 2012. RESULTS: The search gener-
ated 374 references, of which 5 comparative studies met the inclusion criteria. All
were reporting cases of uveal melanoma. Studies were characterized by large dif-
ferences in radiation techniques applied within the studies, and by variation in
patient characteristics within and between studies. Overall, the level of evidence is
low. When compared to iodine-125 or ruthenium-106 brachytherapy, protons did
not provide beneficial effects on overall survival. Proton therapy was although
superior to enucleation: results of two studies showed that 12% more patients
survived over 36 months and 21% more patients survived over 60 months in the
proton group. Vision preservation was observed significantly more frequently after
proton therapy than iodine-125 brachytherapy (97% vs 93.1%, p0.009). Only one
included study reported side effects. Refractory neovascular glaucoma and corneal
perforations were observed after proton therapy and 10.9% eyes treated with PBRT
were enucleated due to complications. No economic evaluation studies were
found. CONCLUSIONS: There is limited evidence on the effectiveness and safety of
proton radiation in patients with ocular melanomas due to the lack of well-de-
signed and well-reported studies. Available comparative studies suggest that pro-
ton beam therapy may be beneficial for patients with uveal melanoma, with, how-
ever, possible serious side effects. There is a need for research establishing its
cost-effectiveness.
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CLINICAL EFFECTIVENESS ANALYSIS OF SUNITINIB FOR THE TREATMENT OF
PANCREATIC NEUROENDOCRINE TUMORS
Walczak J1, Jarosz J1, Lipin´ska M1, Prza˛da-Machno P2, Kroc J2
1Arcana Institute, Cracow, Poland, 2Pfizer Poland, Warsaw, Poland
OBJECTIVES: To compare clinical efficacy and safety of sunitinib (SUN) and best
supportive care (BSC) versus placebo (PL) and best supportive care (BSC) in the
treatment of patients with unresectable or metastatic, well-differentiated pancre-
atic neuroendocrine tumours (pNET) with disease progression. METHODS: The
review was conducted in accordance with the Cochrane Collaboration guidelines
and the Polish Agency for Health Technology Assessment (AOTM) recommenda-
tions. Calculations were performed using the StatsDirect® 2.6.8 statistical package.
RESULTS: As a result of systematic search of publications, 1 primary randomized
clinical trial (subtype II A), satisfying the inclusion criteria was found (Raymond
2011). It was shown that the use of SUNBSC results in a statistically significant
higher clinical efficacy in respect of progression free survival (PFS), overall survival
(OS) and objective response rate in comparison with the control (PLBSC). The
median PFS was over two fold greater in sunitinib treated patients (11.4 months)
than in placebo group (5.5 months). The objective response rate was 9.3% in the
sunitinib group versus 0% in the placebo group. In the sunitinib group 9 deaths
(10%) were reported compared with 21 deaths (25%) in the placebo group (HR 0.40;
95% CI, 0.18 to 0.86). Sunitinib is safe and well-tollerated therapy. The most fre-
quent adverse events in the sunitinib group were diarrhea, nausea, vomiting, as-
thenia, and fatigue. In most cases, analysed adverse events were of low severity
grade. CONCLUSIONS: The results of the presented analysis clearly prove that
sunitinib administered in a 37,5 mg dose is an effective and safe therapy in the
treatment of patients with unresectable or metastatic, well-differentiated pancre-
atic neuroendocrine tumours with disease progression.
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OBJECTIVES: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine ki-
nase inhibitor (TKI) that has proven, in controlled clinical trials, to be effective in
the first-line treatment of patients with advanced or metastatic non-small-cell
lung cancer (mNSCLC) with EGFR activating (EGFR) mutations, showing signifi-
cant improvement of progression-free survival over platinum-based standard che-
motherapy. In those trials, pemetrexed was not included in the platinum-based
chemotherapy regimens used as a comparator, since it was not yet approved for
first line use. Following approval as first line treatment for lung adenocarcinoma,
plus cisplatin, it became the standard for this indication. The aim of this analysis
was to compare the efficacy in reducing the risk of disease progression for patients
with mNSCLC with EGFR mutations treated with erlotinib versus pemetrexed/
cisplatin. METHODS: In the absence of head-to-head trials comparing erlotinib
with pemetrexed/ cisplatin, an indirect comparison methodology was performed
using the Hazard Ratio (HR) - the most appropriate measure to compare time re-
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lated outcomes. Clinical data was collected from EURTAC and JMDB clinical trials,
which compared erlotinib and pemetrexed/ cisplatin, respectively, with different
doublet chemotherapy regimens. Assumptions were used to allow this indirect
comparison, namely, pemetrexed/ cisplatin relative efficacy observed in JMDB ad-
enocarcinoma patients also applies to patients with EGFR mutations and that
different doublet chemotherapy regimens used in the mentioned trials are of
equivalent efficacy. RESULTS: The HR for disease progression of erlotinib versus
pemetrexed/ cisplatin, in patients with mNSCLC and EGFR mutations was 0.41
(95% CI: 0.27–0.62, p 0.001). This is equivalent to a 59% reduction in the risk of
disease progression. CONCLUSIONS: Despite some limitations and uncertainties
associated with indirect comparisons, erlotinib presents itself as a significantly
more effective first-line treatment for mNSCLC patients with EGFR mutations,
showing a significant disease progression risk reduction when compared to pem-
etrexed/ cisplatin.
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OBJECTIVES: This study explores and describes real therapeutic features (preva-
lence, incidence, length of therapy, prescriptions, etc.), treatment effectiveness in
therapy groups and management costs of MRCC patients treated with M-TOR ki-
nase inhibitors. METHODS: The analysis used patients’ data from the National
Health Insurance Fund Administration (NHIFA). Subjects were patients with a di-
agnosis of MRCC (with ICD-10 code C64) (14.794 such patients exist), who filled a
renal cancer drug prescription between Jan 2008 and July 2011 (1.648 patients).
Descriptive methods and Kaplan-Meier analysis for survival and progression free
survival were applied. An assumption was made that progression free survival can
be described by therapy persistence due to the features of treatment lines.
RESULTS: Patients usually filled for first line therapy (mainly sunitinib) with a dose
for a two-month long and second line therapy (mainly sorafenib) with a dose for
one-month long period at one time. Number of sunitinib patients grew significantly
during the analysis period mainly due to new patients. A huge proportion of pa-
tients discontinued the therapy within three months, which shows a high ratio of
non-responsive patients. Comparison of different therapies, examination of pro-
gression free survival curves, showed that first line therapies (sunitinib) have lon-
ger persistence than second line therapies (sorafenib). Therapy persistence was
generally shorter than the period in which patients were on therapy based on filling
of therapies. Progression free survival was longer in case of patients who were on a
therapy for at least 11 months. Difference between therapies in ordinary survival
couldn’t be showed due to the short period of analysis.CONCLUSIONS:Main part of
patients is non-responsive to MRCC therapies in Hungary. We found that there is a
difference between MRCC therapies in progression free survival of MRCC patients.
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OBJECTIVES: The benefits of inhaled corticosteroids (ICS)in patients with asthma
or chronic obstructive pulmonary disease (COPD) are based mainly on their anti-
inflammatory effects. Chronic inflammation has been implicated in the pathogen-
esis of several cancers, including lung cancer and laryngeal cancer. The aim of this
study was to elucidate the association between ICS use and diagnosis of lung
cancer and laryngeal cancer. METHODS: A nested case–control study was con-
ducted based on the Korean national claims database. The eligible cohort consisted
of 792,687 new adult users of inhaled respiratory medications between January1,
2007, and December31, 2010. Patients diagnosed with lung cancer or laryngeal
cancer after initiation of inhaled medication were identified as cases. For each case
individual, up to five control individuals matched for age, sex, diagnosis of asthma
or COPD, Charlson Comorbidity Index scores, number of health care visits, and
initiation date were selected. RESULTS: From the cohort population, 9,177 individ-
uals diagnosed with lung cancer were matched with 37,048 controls. Additionally,
408 individuals with laryngeal cancer and 1,651 controls were matched. ICS use
was associated with a decreased rate of lung cancer diagnosis [adjusted odds ratio
(aOR), 0.79; 95% confidence interval (CI), 0.69–0.90]. Furthermore, the association
between ICS use and decreased risk of lung cancer was dose dependent (P0.0001
for the trend). However, no reduction in the risk of laryngeal cancer among ICS
users was identified (aOR, 1.06; 95% CI, 0.62–1.18). CONCLUSIONS: The use of ICS is
associated with a reduced risk of lung cancer but not of laryngeal cancer.
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OBJECTIVES: To characterize treatment modalities and health outcomes in indi-
viduals treated for unresectable stage III or stage IV melanoma and to compare
these outcomes across patients in the public and private health care systems in
Brasil, respectively. METHODS: This is a multicentre retrospective chart review,
characterizing treatment patterns and clinical outcomes among individuals with
unresectable stage III or stage IV melanoma diagnosed or relapsed between January
1, 2008 and December 31, 2009. All patients had at least two months follow up in 12
private and public centers, divided in South, South-East and North-East regions in
Brazil. Overall survival from time of diagnosis was characterized using a Kaplan-
Meier analysis. Key results are reported stratified by public and private health
systems. RESULTS: Treatment was received by 161 of 165 eligible patients (63 pri-
vate and 98 public). The majority of patients received systemic therapy (76.4%) and
surgery (57.8%). Radiotherapy was received by 37.9% and 9.3% received supportive
care rather than another line of therapy. A larger proportion of private patients
received systemic therapy compared to public patients (92.1% versus 66.3%), spe-
cifically chemotherapy and immunotherapy. Second-line therapy was adminis-
tered to 65% vs. 26.5% of private and public patients respectively. Complete or
partial response was observed in 16.1% of overall first-line patients (22% in private
patients, 11.3% in public patients). Median survival was 14.4 months (95% CI, 10.6-
21.6); 11.5 months for public patients and 19.2 months for private patients (p0.07).
CONCLUSIONS: Overall results demonstrate the lack of effective treatment for
advanced melanoma. Patients treated at private centres received more treatment
and also had a difference in the median survival when compared with those
treated at the public health care. This finding should be better studied in future
research.
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OBJECTIVES: To perform a systematic review and meta-analysis of all randomized
controlled trials comparing the efficacy of Sipuleucel-T versus placebo for asymp-
tomatic or minimally symptomatic metastatic castration-refractory prostate can-
cer (mCRPC). METHODS: Several databases were searched, including MEDLINE,
EMBASE, LILACS, and CENTRAL. The endpoints were overall survival (OS), time to
progression (TTP) and side effects. We performed a meta-analysis (MA) of the pub-
lished data. The results are expressed as Hazard Ratio (HR) or Risk Ratio (RR), with
their corresponding 95% confidence intervals (CI95%). RESULTS: The final analysis
included 3 trials comprising 737 patients. The TTP was similar in patients who
received Sipuleucel-T or placebo (fixed effect: HR0.89; CI95%0.75 to 1.05;
p0.16), with no heterogeneity detected on this analysis (Chi2  2.14, df  2
(P0.34); I2  6%). The results showed a higher overall survival in patients treated
with Sipuleucel-T (fixed effect: HR0.74; CI95%0.61 to 0.89; p0.001; NNT 3). We
found no heterogeneity on this analysis either (Chi2 1.46, df 2 (P0.48); I2 0%).
The incidence of adverse events (grade  3) was the same in both groups.
CONCLUSIONS: Sipuleucel-T prolongs overall survival in patients with asymptom-
atic or minimally symptomatic mCRPC.
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OBJECTIVES: In Germany, not only academic and non-academic hospitals but also
office-based practitioners play an important role in providing care to cancer pa-
tients. Bone metastases (BM) are a late-stage complication of several cancer types
for which the current gold standard treatment are bisphosphonates. Aim of this
study was to investigate the initiation of cancer related bisphosphonate therapy
depending on the type of treatment facility. METHODS: This retrospective cohort
study is based on a purchasable oncology database (IMS®Oncology Analyzer). This
database provides comprehensive insight into cancer patient care with backdata
until 1999. The analysed time period was January 2003 to December 2011. Main
outcome measure was the initiation of bisphosphonate therapy depending on the
type of treatment facility. A multivariate logistic regression model was fitted with
the bisphosphonate therapy as dependent variable and indicator variables for of-
fice-based practitioners, general hospital and academic hospital. Demographic and
clinical data were also analysed and included as confounders. RESULTS: Patients
with BM following breast cancer (BC) (n1957, mean age: 63.9 years), prostate can-
cer (PC) (n1425, mean age: 70.8), non-small-cell-lung cancer (NSCLC) (1,543 pa-
tients, mean age: 63.6) or multiple myeloma (MM) (1,079 patients, mean age: 67.7)
were selected. Of them 1338 (68.3%) of BC, 843 (59.2%) of PC, 795 (51.5%) of NSCLC
and 912 (84.5%) of MM patients received treatment with bisphosphonates. MM
patients have significant higher chances to receive bisphosphonate therapy in
academic hospitals compared to office based practitioners (HR 1.64, p0.01). In PC
and BC, no differences between treatment facilities were found. For NSCLC patients
the chance of bisphosphonate treatment was lower in academic hospital than at
office-based practitioners (HR: 0.59, p0.04). CONCLUSIONS: Factors influencing
the therapy initiation with bisphosphonates have to be identified in order to ensure
optimal treatment of BM. Cancer type may play a role as shown in this study.
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